Research map: Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial

Back to the article

Papers in this map

  1. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia · Stephen G. O’Brien · 2003 · 3596 citations · Cited by this paper
  2. Treatment of adult acute lymphoblastic leukemia—a therapeutic revolution in the making · Hagop M. Kantarjian · 2026 · Cites this paper
  3. Evolutionary considerations for risk stratification in TP53-variant myeloproliferative neoplasms · 2026 · Related
  4. AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance · Thomas O’Hare · 2009 · 1266 citations · Cited by this paper
  5. Rbm5 sustains leukemia stem cells through a Myc-driven transcriptional circuitry · 2026 · Related
  6. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias · Jörge E. Cortes · 2013 · 1147 citations · Cited by this paper
  7. Cohesin haploinsufficiency and inv(16) cooperate to reinforce Fli1 gene transcriptional programs during acute myeloid leukemia initiation and maintenance · 2026 · Related
  8. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial · Jörge E. Cortes · 2018 · 599 citations · Cited by this paper
  9. Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis · 2026 · Related
  10. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs · Delphine Réa · 2021 · 345 citations · Cited by this paper
  11. FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia · 2026 · Related
  12. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring · Elias Joseph Jabbour · 2022 · 293 citations · Cited by this paper
  13. IKZF1N159S is associated with adverse outcomes in patients with myelodysplastic neoplasms · 2026 · Related
  14. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial · Jeffrey Howard Lipton · 2016 · 266 citations · Cited by this paper
  15. Tumor molecular age acceleration is associated with early progression in diffuse large B-cell lymphoma · 2026 · Related
  16. Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008 · Magnus Björkholm · 2011 · 216 citations · Cited by this paper
  17. Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry · 2026 · Related
  18. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial · Jörge E. Cortes · 2021 · 205 citations · Cited by this paper
  19. Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms · 2026 · Related
  20. Management of chronic myeloid leukemia in 2023 – common ground and common sense · Jayastu Senapati · 2023 · 184 citations · Cited by this paper
  21. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients · David J. Dorer · 2016 · 165 citations · Cited by this paper
  22. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL · Andreas Hochhaus · 2023 · 146 citations · Cited by this paper
  23. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia · Jane F. Apperley · 2025 · 133 citations · Cited by this paper
  24. BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia · Gustavo Pessini Amarante-Mendes · 2022 · 108 citations · Cited by this paper
  25. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee · James Louis Januzzi · 2022 · 71 citations · Cited by this paper
  26. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors · J. H. Lipton · 2014 · 58 citations · Cited by this paper
  27. Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia · Hagop M. Kantarjian · 2022 · 47 citations · Cited by this paper
  28. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials · Elias Joseph Jabbour · 2024 · 40 citations · Cited by this paper
  29. Survival with chronic myeloid leukaemia after failing milestones · Michael Lauseker · 2023 · 39 citations · Cited by this paper
  30. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors · Koji Sasaki · 2015 · 33 citations · Cited by this paper
  31. Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor · Aram Bidikian · 2023 · 33 citations · Cited by this paper
  32. The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR :: ABL1 tyrosine kinase inhibitors · Elias Joseph Jabbour · 2023 · 21 citations · Cited by this paper
  33. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors · Fadi G. Haddad · 2024 · 21 citations · Cited by this paper
  34. Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study · Michael J. Hanley · 2023 · 13 citations · Cited by this paper
  35. What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia · Hagop M. Kantarjian · 2023 · 9 citations · Cited by this paper
  36. Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison · Valentín García‐Gutiérrez · 2024 · 8 citations · Cited by this paper
  37. Untitled · Cited by this paper

Source: OpenAlex (CC0)